The creation of retatrutide, a novel dual activator targeting both GLP-1 and GIP receptors, requires a complex several-stage synthetic process. Early routes focused on peptide section coupling, utilizing solid-phase creation methodologies to build the long peptide sequence. Subsequent investigation has explored different approaches, including enzym